1994
Changes in Cerebrospinal Fluid Neurochemistry During Treatment of Obsessive-compulsive Disorder With Clomipramine
Altemus M, Swedo S, Leonard H, Richter D, Rubinow D, Potter W, Rapoport J. Changes in Cerebrospinal Fluid Neurochemistry During Treatment of Obsessive-compulsive Disorder With Clomipramine. JAMA Psychiatry 1994, 51: 794-803. PMID: 7524463, DOI: 10.1001/archpsyc.1994.03950100042004.Peer-Reviewed Original ResearchConceptsCorticotropin-releasing hormoneLong-term treatmentObsessive-compulsive disorderCSF levelsHomovanillic acidCSF monoamine metabolite levelsCentral administrationCerebrospinal fluid levelsSignificant decreaseCSF homovanillic acidMonoamine metabolite levelsCerebrospinal fluid neurochemistryCSF oxytocin levelsOpposite behavioral effectsPharmacologic treatmentSomatostatin levelsMonoamine metabolitesPathophysiologic processesFluid levelsBehavioral effectsOxytocin levelsClomipramine hydrochlorideMetabolite levelsDisordersVasopressin
1993
CSF somatostatin in obsessive-compulsive disorder
Altemus M, Pigott T, L'Heureux F, Davis C, Rubinow D, Murphy D, Gold P. CSF somatostatin in obsessive-compulsive disorder. American Journal Of Psychiatry 1993, 150: 460-464. PMID: 8094599, DOI: 10.1176/ajp.150.3.460.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderCSF somatostatinDrug-free outpatientsSerotonin reuptake inhibitorsSpectrum of disordersSubstantial cognitive deficitsMeasurement of somatostatinPredominant symptomReuptake inhibitorsSomatostatin activitySomatostatin levelsBrain contentPatient subgroupsClinical symptomatologyNormal subjectsNormal volunteersSomatostatinPatientsNeuropharmacological agentsExperimental animalsCognitive deficitsCentral administrationDisordersFunctional significance